Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03993353
Other study ID # 190098
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 7, 2020
Est. completion date March 1, 2029

Study information

Verified date March 2024
Source University of California, San Diego
Contact Khushbu Singh
Phone (858) 246-2604
Email ksingh@health.ucsd.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.


Description:

Immune competent animal models of HNSCC demonstrate that combination PDE-5 inhibitor (tadalafil) and PD-1 inhibitor therapy is more effective than either therapy alone based on the concept of targeting multiple immune repressive abnormalities simultaneously (PD-1 checkpoint and myeloid suppressive pathways). This trial will test the hypothesis that combination PD-1 inhibition and PDE-5 inhibition can be safely co-administered, and secondarily test the hypothesis that the combination of both therapies will be more effective than PD-1 inhibition alone in recurrent/metastatic HNSCC.


Recruitment information / eligibility

Status Recruiting
Enrollment 6
Est. completion date March 1, 2029
Est. primary completion date March 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Selected Inclusion Criteria: - Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck. - Presence of measurable disease. - Life expectancy of greater than 12 weeks - Patients must have normal organ and marrow function Selected Exclusion Criteria: - Prior therapy with an PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting - Uncontrolled central nervous system metastases (stable metastases permitted) - Active autoimmune disease - Chemotherapy =28 days prior to first administration of study treatment and/or monoclonal antibody =8 weeks prior to first administration of study treatment. - Prior daily use of tadalafil or other long-acting PDE5 inhibitors for one month or greater within 3 months of trial enrollment - Current use of all other long-acting PDE5 inhibitors. - Known severe hypersensitivity to tadalafil or any of the excipients of this product - Current treatment with nitrates - Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir. - Current treatment with guanylate cyclase (GC) stimulators such as riociguat. - History of hypotension and/or blindness and/or sensorineural hearing loss during prior treatment with tadalafil or other PDE-5 inhibitors - History of known hereditary degenerative retinal disorders, including retinitis pigmentosa - Prior history of non-arteritic anterior ischemic optic neuropathy - Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential. - History of stroke within prior 6 months. - History of acute myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure - Left ventricular outflow obstructions, such as aortic stenosis and idiopathic hypertrophic subaortic stenosis - Angina requiring treatment with long-acting nitrates - Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration - Unstable angina within 90 days of visit 1 (Braunwald 1989) - Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention - History of any of the following coronary conditions within 90 days of planned tadalafil administration: - Myocardial Infarction - Coronary artery bypass graft surgery - Percutaneous coronary intervention (for example, angioplasty or stent placement) - Any evidence of heart disease (NYHA = Class II as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration - Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of >10 mg/day of prednisone or equivalent) - Prior organ transplantation - Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).

Study Design


Intervention

Drug:
Pembrolizumab
200 mg intravenously every 3 weeks
Tadalafil
10 mg by mouth daily

Locations

Country Name City State
United States UCSD Moores Cancer Center La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Dose Limiting Toxicity (DLT) Rate of dose limiting toxicity at least possibly attributable to study treatment 2 years
Primary Overall Survival (OS) Overall survival at 12 months post-enrollment 12 months
Secondary Response measured by RECIST 1.1 12 months
Secondary Progression free survival 2 years
Secondary Adverse event rates 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients